Loading...
•
Jun 30
Bio-Techne Q4 2025 Earnings Report
Bio-Techne reported Q4 2025 results with slight revenue growth, but a GAAP net loss due to an impairment charge.
Key Takeaways
Bio-Techne saw 4% reported revenue growth in Q4, led by strength in Protein Sciences. However, the quarter resulted in a GAAP net loss due to an $83M impairment related to Exosome Diagnostics. Adjusted EPS rose to $0.53.
Revenue grew 4% to $317M, with 3% organic growth.
GAAP EPS declined to $(0.11) due to impairment costs.
Adjusted EPS increased to $0.53 from $0.49 last year.
Protein Sciences segment led with 6% growth and 43.6% margin.
Bio-Techne
Bio-Techne
Bio-Techne Revenue by Segment
Revenue by Segment
Protein Sciences Revenue
CapyFin.comDiagnostics & Spatial Bio Revenue
CapyFin.com Forward Guidance
Bio-Techne did not issue specific numerical guidance for future quarters but emphasized strategic divestiture and focus on core growth areas amid market uncertainty.
Positive Outlook
- Divestiture of Exosome Diagnostics expected to improve profitability.
- Focus increased on high-growth research and diagnostics tools.
- Strong momentum in proteomics and cell therapy markets.
- Adjusted EPS growth despite market headwinds.
- Cost control and productivity initiatives underway.
Challenges Ahead
- Market uncertainties remain a headwind.
- GAAP earnings significantly impacted by asset impairment.
- Diagnostics segment experienced a revenue decline and margin contraction.
- Product mix challenges affected operating margin.
- No detailed forward revenue or EPS guidance provided.
Revenue & Expenses
Visualization of income flow from segment revenue to net income